Comparison of the efficacy and safety of alfuzosin and tamsulosin in relieving lower urinary tract symptoms in Iraqi patients with benign prostatic hyperplasia (BPH): Observational case reference study
Abstract
Background:The main stay in non-surgical management of benign prostatic hyperplasia (BPH) includes the use of “5-alpha reductase inhibitors” which act by inhibition of the production of dihydroxy testosterone, the active metabolite of testosterone with high affinity to androgen receptors. In addition selective and non-selective alpha receptors inhibitors are also used in the medical treatment of BPH. The basis behind using of alpha blocker is that a substantial proportion of prostatic enlargement is due to stromal hyperplasia containing a principal element of smooth muscle fibers that produce dynamic obstruction. Objectives: The current study was aiming at comparing the effect of selective and nonselective alpha blocking agents, tamsulosin and alfuzosin on size of prostate and “lower urinary tract symptoms” in a sample of Iraqi patients with BPH. Patients and methods: The current observational case reference study was conductedat the department of urology at Al-Hilla teaching hospital, Babylon province, Iraq. The work with this study started on September the 1 st 2018 through July the 15 th 2019. Three groups were included each one enrolled 20 patients with a diagnosis of BPH. The first group included patients who were recently diagnosed to have symptomatic BPH (n = 37) and are on no medical treatment or surgical intervention till time of starting the study. The second group included 45 patients already on medical treatment with the non-selective alfuzosin alpha blocking…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.